Q-omics provides the consensus-scored RNY3P16 profile across patient tissues and cancer cell-line models. RNY3P16 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNY3P16 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RNY3P16 RNA expression shows 13,340 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where RNY3P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNY3P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNY3P16 survival associations across molecular data types. RNY3P16 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNY3P16 RNA expression–survival associations across cancer types. High RNY3P16 expression shows unfavorable associations in KIRC, UCEC, LGG, ACC and ESCA, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNY3P16 RNA expression.
This table summarizes RNY3P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNY3P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNY3P16 shows lower tumor expression in UCEC and higher tumor expression in KIRC, HNSC, CHOL, LIHC and KIRP. The KIRC box plot shows higher RNY3P16 RNA expression in tumor versus normal tissue (log2 FC = +1.426, t-test p < 0.001).
This table shows molecular features associated with RNY3P16 in patient tissues and cancer cell lines. In patient samples, RNY3P16 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
